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Abstract
Background: It was intended to study the structure of the symptoms in patients suspected of having SARS-CoV-2 virus infection, as well as to find 
any correlations between the clinical, paraclinical and radiological manifestations in positive versus negative patients, in order to further facilitate the 
diagnosis and triage of patients.
Material and methods: 101 patients seeking medical attendance at the COVID-19 Triage Center in Chisinau have been examined, presenting various 
respiratory symptoms. The frequency of symptoms and the results of the paraclinical investigations were evaluated based on the results of the PCR tests 
for SARS-CoV-2 infection and the assessment of correlations (Pearson).
Results: Out of 101 subjects, 50 tested SARS-CoV-2 positive, and the remaining 51 – negative. The clinical manifestations of SARS-CoV-2 suspects were 
as follows: fatigue – 72%, sweating – 54%, chills – 52%, fever – 49%, subfebrility – 39%, myalgias and arthralgias – 37%, cough – 35% (sputum – 17% 
and hemoptysis – 2%), dyspnea – 34%, chest pain – 23%, anosmia – 12%, headache – 11%, dyspeptic syndrome – 8%. Infiltrates on chest radiography 
were found in 22% of cases.
A weak inverse correlation (R = -0.22, P <0.05) between the leukocyte count and SARS-CoV-2 test results was found. An average direct correlation 
between the presence of fever (R = 0.36, P <0.05) and a positive COVID-19 test was also noticed.
Conclusions: Certain symptoms such as anosmia were more commonly seen in patients with positive COVID-19 tests. The absence of pulmonary 
infiltrates and the presence of dyspnoea have been negative predictive factors for COVID-19. Leukopenia has been noticed only in  SARS-CoV-2 positive 
patients. Subfebrility has not shown a predictive significance of COVID-19.
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Introduction
COVID-19 is a respiratory condition where pulmonary 
manifestations are the main clinical presentations of the di-
sease. According to the reported studies, SARS-CoV-2 in-
fection is not limited to the respiratory system, it does affect 
other organs, as well. Renal dysfunction, gastrointestinal 
complications, liver failures, cardiac manifestations, neuro-
logical abnormalities and hematological manifestations are 
among the reported extrapulmonary features [1].
Studies report a timeframe of 6 to 41 days from the onset 
of COVID-19 symptoms until death, with a median of 14 
days [2].
The most commonly reported symptoms at the onset of 
COVID-19 disease are fever, cough, and fatigue, while other 
symptoms include the presence of sputum, headache, he-
moptysis, diarrhea, dyspnea, and lymphopenia [3-5].
Laboratory tests showed leukopenia, of which 70% 
were neutrophils. Additionaly, increased values of blood 
C-reactive protein were observed. A high sedimentation rate 
of erythrocytes and elevated D-dimers have also been found 
[6].
Studies report the presence of various common symp-
toms for many viral respiratory diseases such as: fever – 83%, 
cough – 82%, dyspnea – 31%, myalgia – 11%, confusion – 
9%, headache – 8%, sore throat – 5%, rhinorrhea – 4%, chest 
pain – 2%, diarrhea – 2%, nausea and vomiting – 1% [7].
Therefore, the early diagnosis of SARS-CoV-2 infection 
has become a challenge for the clinician, and the delayed re-
sults of the PCR tests, as well as the presence of false-nega-
tive results, have made it even more difficult to establish the 
diagnosis. Currently there is no test with a specificity and 
sensitivity of 100% [8].
Thus, it was intended to study the structure of symptoms 
in patients suspected of having the SARS-CoV-2 virus in-
fection, and to find the correlations between the clinical and 
paraclinical manifestations in positive versus negative pati-
ents, in order to further facilitate the diagnosis and triage of 
patients.
63
ORIGINAL  ReseARch I. Sirbu et al. Moldovan Medical Journal. October 2021;64(4):62-65
 
Material and methods
The current study involved 101 patients (51 men and 
50 women), suspected of having the SARS-CoV-2 infecti-
on, who sought medical attendance at the Covid-19 Center 
in Chisinau between April and July 2020, in a state of mild 
and average severity, presenting various respiratory symp-
toms. The patients’ age varied between 18 and 84 (the ave-
rage age being 49.3 years). The disease history was collected 
and a paraclinical examination was performed (full blood 
count, chest radiography, ECG, SARS-CoV-2 PCR test). The 
frequency of symptoms was assessed according to the results 
of the PCR tests for SARS-CoV-2 and the assessment of the 
correlations (Pearson) between clinical and paraclinical data.
The statistical data was processed using the SPSS pro-
gram, with a value of „p” less than 0.05 being considered sta-
tistically significant.
Results
51 negative and 50 positive tests for SARS-CoV-2 were 
obtained. The clinical manifestations (in descending order) 
of SARS-CoV-2 positive patients were as follows: fatigue – 
72%, sweating – 54%, chills – 52%, fever – 49%, subfebrility 
– 39%, myalgias and arthralgias – 37%, cough – 35% (spu-
tum – 17% and hemoptysis – 2%), dyspnea – 34%, chest pain 
– 23%, anosmia – 12%, headache – 11%, dyspeptic syndro-
me – 8% (fig. 1). The presence of infiltrates on chest radio-
graphy was identified by performing a chest radiography in 
21 patients, of which 12 patients were COVID-19 positive 
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Fig. 1. Structure of symptoms according to the results of the 
SARS-CoV-2 test
The number of days from the onset of symptoms until 
testing varied from 1 to 60 days (average length 7.08 days), 
the results being different depending on the test result. Thus, 
it was observed that the earlier the onset of symptoms, the 
greater the chances of testing positive for COVID-19 (fig. 2).
A great number of the suspects presented with multiple 
comorbidities, making it more difficult to establish the dia-
gnosis, many symptoms being similar for other pathologies 
(fig. 3).
In 55% of the patients with a negative test, at least one 
concomitant pathology has been detected. And in those with 
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Fig. 3. Structure of multiple morbidities  
in COVID-19 suspects
The O2 saturation of the patients was measured on ad-
mission, thus values between 83% and 100% were obtai-
ned (the average SaO2 being 96.83%). A weak correlation 
was measured between the saturation on admision and the 
SARS-CoV-2 test result, being statistically insignificant (R = 
0.06; p> 0.05).
A full blood count was performed in all patients, leuko-
cyte values and erythrocyte sedimentation rate (ESR) were 
also investigated. A weak, statistically significant inverse cor-
relation was found between the leukocyte numbers and the 
SARS-CoV-2 test results (R = -0.222; p <0.05), (fig. 4).
Lymphocyte values were also assessed compared to the 
COVID-19 test results. No correlation was determined be-
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Fig. 4. COVID-19 test results and leukocyte values
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Fig. 5. COVID-19 test results and lymphocyte values
The correlation between the SARS-CoV-2 test results 
and the ESR values was also measured, obtaining a weak 
direct correlation, being statistically insignificant (R = 0.04; 
p> 0.05).
A mean direct correlation (R = 0.41, P <0.05) was found 
between dyspnea and the presence of pulmonary infiltrates 
on chest radiography in SARS-CoV-2 positive patients and 
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Fig. 6. Correlation between dyspnea and pulmonary  
infiltrates based on the test results
An average direct correlation was noticed between fe-
ver (R = 0.31, P <0.05) and pneumonia in the SARS-CoV-2 
positive patients, with its absence in subjects with negati-
ve test results. An average direct correlation between fever 
(R = 0.36, P <0.05) and a positive COVID-19 test result was 
also observed. Subfebrility was found to be of approximate-
ly the same frequency in patients with positive and negative 
tests for COVID-19.
Discussion
Within the current observational study based on data 
gained from 101 patients suspected of having a COVID-19 
infection, the presence of many symptoms common for res-
piratory tract infections was noticed, the most common of 
them being fever, signs of general intoxication and cough. 
Also, some symptoms such as anosmia have been detected 
much more frequently in patients with positive SARS-CoV-2 
test results. Other studies in the field have shown similar re-
sults [9].
Furthermore, dyspnea and chest pain were more com-
mon in patients with negative SARS-CoV-2 test results. This 
phenomenon could be explained by the presence of multiple 
concomitant pathologies that were also suspected, such as is-
chemic heart disease, cardiac failure or pulmonary obstruc-
tive pathologies [10].
Low leukocyte values in suspect patients could be a strong 
predictor of SARS-CoV-2 infection, as all 9 patients with le-
ukopenia were diagnosed with COVID-19. Leukocytosis has 
been found more frequently in patients with negative test re-
sults, which could be explained by exacerbation of chronic 
conditions, such as asthma, chronic obstructive pulmonary 
disease or some acute conditions such as pyelonephritis.
The values of lymphocytes in suspect patients was of no 
significance in establishing the presumptive diagnosis of 
COVID-19, as lymphopenia and lymphocytosis were also 
present in patients with negative test results. These results re-
fer to patients with a mild and average severity of COVID-19 
[11].
Dyspnea was more common in patients with negative 
SARS-CoV-2 tests, being present in patients who also had 
radiological imaging findings, but the presence of dyspnea 
without radiological changes was also a negative predictor 
of COVID-19. Fever and subfebrility were found in 80% of 
patients.
Conclusions
1. Anosmia was found 5 times more frequently in test-
positive patients, thus being a strong predictor in a suspect 
case of COVID-19. Other symptoms were found with ap-
proximately the same frequency in patients with negative 
COVID-19 test results.
2. Dyspnea without any lung damage is 3.6 times more 
common in patients with negative COVID-19 test results.
3. Lung damage was 1.3 times more common in patients 
with positive versus negative test results.
4. 33% of patients with COVID-19 and pneumonia had 
no dyspnea.
5. Leukopenia was found in 9% of suspects and only in 
patients with positive SARS-CoV-2 test results.
6. Fever was 1.8 times more common in patients with 
positive COVID-19 test results;  however, subfebrility was 
found in a ratio of 1:1 within the study group.
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